



HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 616

PRINTERS NO. 2760

PRIME SPONSOR: Owlett

COST / (SAVINGS)

| FUND | FY 2019/20 | FY 2020/21 |
|--------------|-------------------|-------------------|
| General Fund | See Fiscal Impact | See Fiscal Impact |

SUMMARY:

House Bill 616, Printer's Number 2760 amends Section 4(2) (Schedules of Controlled Substances-Schedule II) of The Controlled Substance, Drug, Device and Cosmetic Act of 1972 (P.L. 233, No. 64) by adding the drug Carfentanil.

ANALYSIS:

HB 616 adds the drug Carfentanil to the list of Schedule II controlled substances in the Controlled Substance, Drug, Device and Cosmetic Act.

This act would take effect immediately.

FISCAL IMPACT:

Enactment of this legislation may have a minimal fiscal impact on Commonwealth funds; however, it is impossible to determine exactly how many additional individuals would now be charged, convicted and sentenced of a violation of the Controlled Substance, Drug, Device and Cosmetic Act. Carfentanil is synthetic opioid (fentanyl- related substance) and is currently listed as a Schedule II Controlled Substance at the federal level.

PREPARED BY: Jenny P. Stratton
House Appropriations Committee (R)

DATE: December 13, 2019

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.